Description: The eBio5E10 monoclonal antibody reacts with human CD90, also known as Thy-1 (thymus cell antigen-1). CD90 is a 25-35 kD receptor expressed on thymocytes, CD34+ prothymocytes, hematopoietic stem cells, neurons, a small subset of human fetal liver cells, cord blood cells, and bone marrow cells. CD90 is expressed on a subset of immature, CD34+ cells and a distinct subset of mature CD34- cells that are CD3+CD4+. The CD90+CD34+ population is enriched for cells capable of long-term culture. CD90 is involved in regulation of adhesion and signal transduction by T cells. Applications Reported: This eBio5E10 (5E10) antibody has been reported for use in flow cytometric analysis. Applications Tested: This eBio5E10 (5E10) antibody has been pre-titrated and tested by flow cytometric analysis of human erythroleukemia (HEL) cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.CD90 (Thy 1) antigen is a GPI linked glycoprotein member of the Immunoglobulin super family. It is expressed in murine T cells, thymocytes, neural cells, Kupffer ft.s cells and fibroblasts. Thy 1 may play a role in cell-cell or cell-ligand interactions during synaptogenesis and other events in the brain.
|4° C, store in dark, DO NOT FREEZE!|
|PBS with 0.1% gelatin, 0.2% BSA and 0.09% sodium azide; pH 7.2|
For Research Use Only.
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok